Vanguard Group
CLYM

Vanguard Group’s Climb Bio CLYM Stock Holding History

Vanguard Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$5.36M Buy
1,340,504
+24,693
+2% +$59.3K ﹤0.01% 3227
2025
Q3 		$2.64M Sell
1,315,811
-15,439
-1% -$28.7K ﹤0.01% 3492
2025
Q2 		$1.65M Sell
1,331,250
-171,306
-11% -$213K ﹤0.01% 3595
2025
Q1 		$1.83M Sell
1,502,556
-3,701
-0.2% -$6K ﹤0.01% 3516
2024
Q4 		$2.71M Sell
1,506,257
-18,611
-1% -$67.3K ﹤0.01% 3475
2024
Q3 		$7.76M Buy
1,524,868
+1,198,487
+367% +$8.48M ﹤0.01% 3082
2024
Q2 		$2.32M Buy
326,381
+15,895
+5% +$106K ﹤0.01% 3508
2024
Q1 		$851K Hold
310,486
– – ﹤0.01% 3865
2023
Q4 		$838K Buy
310,486
+665
+0.2% +$1.73K ﹤0.01% 3888
2023
Q3 		$815K Buy
309,821
+35,304
+13% +$96.3K ﹤0.01% 3906
2023
Q2 		$769K Hold
274,517
– – ﹤0.01% 3979
2023
Q1 		$796K Hold
274,517
– – ﹤0.01% 3989
2022
Q4 		$1.01M Buy
274,517
+125
+0% +$371 ﹤0.01% 3912
2022
Q3 		$886K Hold
274,392
– – ﹤0.01% 4045
2022
Q2 		$829K Sell
274,392
-30,406
-10% -$144K ﹤0.01% 4147
2022
Q1 		$2.56M Sell
304,798
-1,557
-0.5% -$14.5K ﹤0.01% 3860
2021
Q4 		$3.2M Buy
306,355
+106,761
+53% +$1.59M ﹤0.01% 3849
2021
Q3 		$3.59M Buy
+199,594
New +$4.12M ﹤0.01% 3837

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group's CLYM Position: Q4 2025 in Review

Vanguard Group increased its Climb Bio (CLYM) stake by 1.9% in Q4 2025, buying an estimated $59.3K and bringing the position to 1,340,504 shares worth $5.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3227.

Vanguard Group first reported a position in CLYM in Q3 2021 and has held it in 18 quarters since. The position peaked at $7.76M in Q3 2024. 65 funds tracked by Wall St. Rank hold CLYM as of Q4 2025.

  • Vanguard Group held 1,340,504 shares of Climb Bio worth $5.36M as of Q4 2025.
  • Vanguard Group bought 24,693 Climb Bio shares in Q4 2025, an estimated $59.3K.
  • Climb Bio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3227 holding.
  • Vanguard Group first reported a position in Climb Bio in Q3 2021 and has held it in 18 quarters since.
  • Vanguard Group's Climb Bio position peaked at $7.76M in Q3 2024.
  • 65 funds tracked by Wall St. Rank held Climb Bio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.